PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of arthrestherBioMed Centralbiomed central web sitesearchsubmit a manuscriptregisterthis articleArthritis Research & Therapy
 
Arthritis Res Ther. 2006; 8(4): 402.
Published online 2006 June 1. doi:  10.1186/ar1981
PMCID: PMC1779376

Correction: Fish oil: what the prescriber needs to know

It has been brought to our attention that there were a number of typographical errors in one section of our recent article [1] published in December 2005.

All corrections apply to the section entitled, 'Biochemical rationale; Eicosanoids: cyclo-oxygenase pathway'.

The second paragraph should read:

The usual substrate for the COX isozymes is the n6 LC PUFA arachidonic acid (AA; C20:4n-6). Eicosapentaenoic acid (EPA; C20:5n-3), which is present in fish oil, differs from AA only by the presence of its n3 bond (Fig. 1).

The last sentence of the third paragraph should read:

Thus, the net effect of fish oil is to reduce the production of proinflammatory and pro-thrombotic eicosanoids (PGE2 and TXA2, respectively) but not the vascular patency factor prostacyclin (PGI2; Fig. 2).

Finally, the first 20-Carbon fatty acid homologue pictured in Figure 1 (C20:3 n-9) is eicosatrienoic acid, rather than oleic acid.

References

  • Cleland LG, James MJ, Proudman SM. Fish oil: what the prescriber needs to know. Arthritis Research & Therapy. 2006;8:202. doi: 10.1186/ar1876. [PMC free article] [PubMed] [Cross Ref]

Articles from Arthritis Research & Therapy are provided here courtesy of BioMed Central